ES2186796T3 - Procedimiento para el tratamiento del asma alergica. - Google Patents

Procedimiento para el tratamiento del asma alergica.

Info

Publication number
ES2186796T3
ES2186796T3 ES96926134T ES96926134T ES2186796T3 ES 2186796 T3 ES2186796 T3 ES 2186796T3 ES 96926134 T ES96926134 T ES 96926134T ES 96926134 T ES96926134 T ES 96926134T ES 2186796 T3 ES2186796 T3 ES 2186796T3
Authority
ES
Spain
Prior art keywords
treatment
allergic asthma
procedure
ige
antigonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96926134T
Other languages
English (en)
Other versions
ES2186796T5 (es
Inventor
Robert B Fick Jr
Paula M Jardieu
Monika B Schoenhoff
Steven J Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2186796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2186796T3 publication Critical patent/ES2186796T3/es
Publication of ES2186796T5 publication Critical patent/ES2186796T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN PROCEDIMIENTOS PARA EL TRATAMIENTO DEL ASMA ALERGICO CON ANTAGONISTAS DE IGE, INCLUYENDO ANTICUERPOS ANTI IGE, VARIANTES DE IGE, ANTAGONISTAS PEPTIDICOS, PEPTIDOMIMETICOS Y OTRAS MOLECULAS PEQUEÑAS.
ES96926134T 1995-07-27 1996-07-24 Procedimientos para el tratamiento del asma alergica. Expired - Lifetime ES2186796T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US508014 1995-07-27

Publications (2)

Publication Number Publication Date
ES2186796T3 true ES2186796T3 (es) 2003-05-16
ES2186796T5 ES2186796T5 (es) 2009-04-01

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96926134T Expired - Lifetime ES2186796T5 (es) 1995-07-27 1996-07-24 Procedimientos para el tratamiento del asma alergica.

Country Status (16)

Country Link
EP (1) EP0841946B2 (es)
JP (1) JP4153560B2 (es)
CN (2) CN101172099B (es)
AR (1) AR003468A1 (es)
AT (1) ATE225185T1 (es)
AU (1) AU715338B2 (es)
CA (1) CA2226624C (es)
DE (1) DE69624116T3 (es)
DK (1) DK0841946T4 (es)
ES (1) ES2186796T5 (es)
IL (1) IL122733A (es)
MX (1) MX9800760A (es)
PT (1) PT841946E (es)
RU (1) RU2229288C2 (es)
WO (1) WO1997004807A1 (es)
ZA (2) ZA966075B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6630140B1 (en) * 1998-03-10 2003-10-07 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
CA2676843A1 (en) * 2007-01-29 2008-08-07 Valtion Teknillinen Tutkimuskeskus Method for producing novel ige based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
AU2008340429C1 (en) * 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
DK2222315T3 (da) * 2007-12-21 2013-07-08 Cangene Corp Stabiliserede faktor-ix-formuleringer indeholdende trehalose
CN102014965B (zh) 2008-04-29 2015-11-25 阿森迪斯药物生长障碍股份有限公司 Peg化的重组人生长激素化合物
BR122018013284B1 (pt) * 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
LT2512450T (lt) 2009-12-15 2018-04-25 Ascendis Pharma Endocrinology Division A/S Sausa augimo hormono kompozicija, laikinai prijungta prie polimero nešiklio
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
DK2691112T3 (en) * 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
EP2771029A4 (en) * 2011-10-25 2015-07-01 Onclave Therapeutics Ltd ANTIBODY FORMULATIONS AND METHOD THEREFOR
US10987425B2 (en) 2013-09-27 2021-04-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting human growth hormone immunoglobulin conjugate
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
SI3220892T1 (sl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Oblike odmerjanja dolgotrajno delujočega rastnega hormona
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
JP7263312B2 (ja) 2017-07-25 2023-04-24 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－１５タンパク質複合体医薬組成物およびその使用
SG11202007564VA (en) * 2018-02-09 2020-09-29 Genentech Inc Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
WO2020092233A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
EP4180454A4 (en) 2020-07-10 2024-10-02 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige engineered antibody and application thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
ES2219640T3 (es) * 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.

Also Published As

Publication number Publication date
EP0841946B1 (en) 2002-10-02
DE69624116D1 (de) 2002-11-07
DK0841946T3 (da) 2003-02-10
DE69624116T3 (de) 2009-07-09
CN101172099B (zh) 2012-02-15
JPH11510172A (ja) 1999-09-07
ES2186796T5 (es) 2009-04-01
CA2226624C (en) 2013-07-16
CN101172099A (zh) 2008-05-07
AU6638196A (en) 1997-02-26
DK0841946T4 (da) 2009-02-16
AR003468A1 (es) 1998-08-05
MX9800760A (es) 1998-04-30
RU2229288C2 (ru) 2004-05-27
DE69624116T2 (de) 2003-06-18
AU715338B2 (en) 2000-01-20
IL122733A (en) 2001-09-13
CA2226624A1 (en) 1997-02-13
ZA966240B (en) 1998-01-23
EP0841946B2 (en) 2008-10-15
CN101172100A (zh) 2008-05-07
JP4153560B2 (ja) 2008-09-24
IL122733A0 (en) 1998-08-16
PT841946E (pt) 2003-02-28
ATE225185T1 (de) 2002-10-15
WO1997004807A1 (en) 1997-02-13
EP0841946A1 (en) 1998-05-20
ZA966075B (en) 1998-01-19

Similar Documents

Publication Publication Date Title
ES2186796T3 (es) Procedimiento para el tratamiento del asma alergica.
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
DE69832158D1 (de) Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
DE69927960D1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
BR0011838A (pt) Elementos misturadores estáticos empilhados
DE69837855D1 (de) Apolipoprotein-a-i-agonisten und ihre anwendung zum behandeln von dyslipidämischer erkrankung
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69738331D1 (de) Therapeutische anwendungen von laminin und von proteinfragmenten die von laminin abgeleitet sind
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
DE69731463D1 (de) Rekombinante ribonuklease proteine
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
PT782630E (pt) Gene da doenca poliquistica do rim
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ATE160673T1 (de) Roggenmehl
ES2165551T3 (es) Bacillus sp. ac13 alcalofilo y xilanasa obtenida a partir de dicha especie.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE103930T1 (de) Modifizierte proteine.